الحملات
View Allالوثائق
View Allالمركز الإعلامي
View All
SFDA CEO Discusses Opportunities for Cooperation in Biotechnology and Advanced Therapies with Korean Companies
The CEO of the Saudi Food and Drug Authority (SFDA), H.E. Dr. Hisham S. Aljadhey, held a roundtable meeting with executives and representatives from...SFDA Organizes 6th Regulatory Research Day 2026 with Participation from 25 Government, Academic, and Research Entities
The Saudi Food and Drug Authority (SFDA) organized the sixth edition of Regulatory Research Day 2026 at its headquarters in Riyadh. Held under the...
SFDA Grants Breakthrough Designation of a Drug Targeting the Treatment of Certain Types of Cancer Under the Breakthrough Program
The Saudi Food and Drug Authority (SFDA) has announced its approval to designate a drug under the Breakthrough Medicines Program for the treatment of...
SFDA Grants Breakthrough Designation to "Povetacicept" for Adults with Primary Immunoglobulin A Nephropathy
The Saudi Food and Drug Authority (SFDA) has granted Breakthrough Designation to “Povetacicept”, developed by Vertex Pharmaceuticals Inc., under the...
SFDA and Saudi NIH Launch Five Initiatives to Advance Clinical Trials and Accelerate Innovative Medicines Development in Saudi Arabia
H.E. Dr. Hisham S. Aljadhey, CEO of the Saudi Food and Drug Authority (SFDA), launched a number of strategic initiatives in clinical trials in...
SFDA Grants Breakthrough Designation to "Wilsirdli" for Early, Advanced, and Metastatic ER+/HER2- Breast Cancer
The Saudi Food and Drug Authority (SFDA) has approved a request by Roche Pharmaceuticals to designate "Wilsirdli" under its Breakthrough Medicine...
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.